Insulin-Like Growth Factor Binding Protein-2: A Possible Regulator of Invasive Growth in Glioblastoma by Tsuyoshi Fukushima & Hiroaki Kataoka
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
19 
Insulin-Like Growth Factor Binding Protein-2: 
 A Possible Regulator of Invasive  
Growth in Glioblastoma 
Tsuyoshi Fukushima and Hiroaki Kataoka 
Section of Oncopathology and Regenerative Biology, Department of Pathology,  
Faculty of Medicine, University of Miyazaki, 
Japan 
1. Introduction 
Glioblastoma is the most common malignant brain tumor and has an extremely lethal 
course (Clark et al., 2010).  Although genetic abnormalities in p53, Akt, phosphatase and 
tensin homolog deleted from chromosome 10 (PTEN), and epidermal growth factor receptor 
that are common to various cancers are also found in glioblastoma, the prime cause of 
glioblastoma’s malignant features and conclusive treatment targets have yet to be 
determined.  Better understanding of non-major signal pathways involved in glioblastoma 
could thus provide breakthroughs in treatment strategies.  Insulin-like growth factor 
binding protein-2 (IGFBP2) was originally reported to be a modulator of the action of 
insulin-like growth factors (IGFs), but IGF-independent effects of IGFBP2 on cellular 
proliferation, apoptosis, metabolism, and mobility have since been reported in pathological 
conditions, including cancers.  Recent studies of gene expression microarray revealed that 
elevated expression of IGFBP2 occurs in gliomas, and is associated with increasing grades of 
malignancy with significant overexpression in glioblastomas (Fuller et al., 1999; Sallinen et 
al., 2000).  Subsequent studies have suggested that IGFBP2 may be one of the proteins that 
play an important role in malignant phenotypes of glioblastoma cells (Fukushima & 
Kataoka, 2007). 
This chapter highlights key examples of recent biological and epidemiological research 
focusing on IGFBP2 in brain tumors and reviews more specialized studies on the 
fundamental role of IGFBP2 in glioma progression. 
2. Structure and physiological functions of IGFBP2 
2.1 Human insulin-like growth factor binding proteins (IGFBPs) 
IGFBPs are a family of six proteins present in plasma and bodily fluids that bind insulin-like 
growth factor-I (IGF-I) and IGF-II with high affinity (Table 1) (Hwa et al., 1999; Firth & 
Baxter, 2002; Fukushima & Kataoka, 2007).  By interacting with IGFs, the IGFBPs modulate 
distribution and activity of IGFs in various tissues and bodily fluids, thereby controlling 
their biological function in vivo (Clemmons 1998; Kelley et al., 2002). IGFBPs in IGFBP/IGF 
complexes can be cleaved at specific sites by various proteinases (Bunn et al., 2003).  This 
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IGFBP cleavage might be an important regulatory mechanism of pericellular IGF function, 
as IGFBP proteolysis releases IGF from the IGFBP/IGF complexes (Lee et al., 1996; Bunn et 
al., 2003; Fowlkes et al., 2004; Mark et al., 2005; Nakamura et al., 2005).  Therefore, IGFBPs 
both positively and negatively regulate IGF function. 
 
 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6 
Gene location 7p13-p12 2q33-q34 7p13-p12 17q12-q21.1 2q33-q36 12q13 
mRNA (kbp) 1.6 1.4 2.6 2.2 6.3 1 
MW (kDa) 25 31 43-45 24 29 28-30 
RGD motif (+) (+)     
Heparin 
binding 
(+) (+) (+) (+) (+) (+) 
Phospho. site (+)  (+)  (+)  
NLS   (+)  (+)  
N-
Glycosylation 
  (+) (+)   
O-
Glycosylation 
    (+) (+) 
Table 1. Summary of IGFBP family.  MW, molecular weight of mature protein.  Phosopho. 
site, presumed phosphorylation site.  NLS, nuclear localization signal. 
2.2 Molecular properties and physiological functions of IGFBP2 
2.2.1 Synthesis, structure and distribution of IGFBP2 
The IGFBP2 precursor is 36-kDa (328 amino acid residues) in size and consists of a signal 
peptide and three distinct regions: the highly conserved N-terminal region (IGFBP homolog 
domain, amino acid residues 43-136); the highly conserved C-terminal region with a 
thyroglobulin type 1 repeat (amino acid residues 229-309); and an intervening region with 
four major cleavage sites (Bunn et al., 2003; Mark et al., 2005) (Figure 1).  The N-terminal and 
C-terminal domains are cysteine-rich and globular, both of which have IGF-binding 
property.  Mature IGFBP2 is a 31.4-kDa protein and is the second most abundant IGFBP 
found in serum. 
 
 
Fig. 1. Molecular structure of human IGFBP2.  Amino acid positions of mature IGFBP2 
protein are indicated.  Integrin binding RGD motif is also shown. 
Although IGFBP1, IGFBP3, and IGFBP5 each have phosphorylation sites, IGFBP2 does not.  
IGFBP2 does, however, have an arginine-glycine-aspartic acid (RGD) motif, which binds to 
cell surface integrins, and a heparin-binding domain, which facilitates association with 
extracellular matrices (Figure 1).  Both regions are able to localize IGFBP2 and IGFBP2/IGF 
complexes on/around the cell surface (Schutt et al., 2004; Russo et al., 2005; Wang et al., 
2006).  Among the six IGFBPs, only IGFBP1 and IGFBP2 possess a RGD motif (Table 1). 
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IGFBP2 is widely expressed in the fetus where its expression is reported to closely parallel 
that of IGF-II (Wood et al, 1992, 1993; Lee et al., 1993).  IGFBP2 is predominantly expressed in 
the early post-implantation epiblast, the apical ectodermal ridge, the progenitors of spleen 
and liver, and fetal astroglial cells (Wood et al., 1992; Lee et al., 1993).  Fetal epithelial cells 
and epidermal progenitor cells abundantly express IGFBP2, which also participates in the 
regulation of hair follicle development (Harris et al., 2010).  The expression of IGFBP2 
decreases significantly after birth, but gradually increases again, especially after the age of 
sixty, and found in plasma, seminal plasma, milk and cerebrospinal fluid (Blum et al., 1993; 
Schwander & Mary, 1993; van den Beld et al., 2003). 
2.2.2 Regulation of IGFBP2 expression 
The IGFBP2 gene is located on chromosome 2q33-q34 near that of IGFBP5 (Garner et al., 
2008).  The promoter region lacks TATA box and CAAT boxes, but contains GC-rich 
sequences and therefore putative Sp1 binding sites.  Portions of the promoter responsible for 
dexamethasone-induced transcriptional activity and IGF-induced stimulation of 
transcription have also been reported (Mouhieddine et al., 1996).  Other possibly important 
promoter regions contain binding sites for AP-4 and nuclear factor κB (NF-κB) (Cazals et al., 
1999).  The relationship between IGFBP2 expression and loss of tumor suppressor gene 
function has been recently elucidated (Perks et al., 2007; Moore et al., 2009) and hypoxic 
microenvironment may also upregulate IGFBP2 gene expression (Feldser et al., 1999).  These 
lines of evidence indicate that upregulated IGFBP2 gene expression should occur in injured 
tissue and particularly in tumors. 
2.2.3 Proposed physiological functions of IGFBP2 
By virtue of its IGF binding capacity, IGFBP2 was initially considered to be an inhibitory 
factor of IGFs, particularly of IGF-II with KD values for IGF-I and IGF-II to be 1.14 and 0.37, 
espectively (Hwa et al., 1999; Russo et al., 2005).  However, it was subsequently found to 
prolong the half-life of IGFs.  The binding between IGFs and IGFBP2 is reversible, and IGFs 
are released when IGFBP2 is processed at its central region cleavage sites by serine 
proteinases including thrombin and prostate specific antigen (human tissue kallikrein 3) 
(Clemmons et al., 1998; Cohen et al., 1992, Zheng et al., 1998) or matrix metalloproteinase 
(MMP) (Nakamura et al., 2005).  As IGFBP2 can associate with cell surface integrins via its 
RGD motif, IGFBP2 could in theory not only be an IGF inhibitor but also provide an IGF 
reservoir at the cell surface to maintain efficient IGF activity in the pericellular 
microenvironment.  Therefore, interaction between integrins and IGFBP2, cleavage of 
IGFBPs by proteases, and other factors that could influence the affinity of IGFBP2 for IGFs 
may be important regulatory mechanisms of pericellular IGF function.  On the other hand, 
IGFBP2 has also been reported in several studies to have a cytosolic or perinuclear 
localization, suggesting that IGFBP2 may also have IGF-independent functions (Hoeflich et 
al., 2004; Fukushima & Kataoka, 2007; Migita et al., 2010). 
IGFBP2 knockout mice are both viable and fertile, and do not show significant differences in 
prenatal or postnatal body growth (Wood et al., 1993, 2000).  However, detailed analyses of 
the knockout mice revealed decreased spleen weight and increased liver weight (Wood et 
al., 2000).  Interestingly, male IGFBP2 knockout mice have shorter femurs than their control 
mouse counterparts, and also have significantly enhanced levels of PTEN in their 
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osteoblasts and osteoclasts (DeMambro et al., 2008).  Recent studies also revealed that 
IGFBP2 likely has a crucial regulatory role in glucose metabolism as might be expected since 
IGFBP2 is regulated by leptin, secreted by visceral white adipocytes, and contributes to the 
prevention of diet-induced obesity as well as having anti-diabetic effects (Hedbacker et al., 
2010; Li & Picard, 2010).  
3. Roles of IGFBP2 in progression of gliomas 
3.1 Expression of IGFBP2 in tumors 
3.1.1 Enhanced expression of IGFBP2 in malignancies of various organs 
To date, there is accumulating evidence to suggest that IGFBP2 is involved in tumor 
progression.  Increased serum/plasma levels of IGFBP2 are associated with many malignant 
tumors of various organs, including prostate (Cohen et al., 1993), ovary (Lancaster et al., 
2006), colon (Mishra et al., 1998), breast (Busund et al., 2005), lung (Lee et al., 1999), skin 
(Harris et al., 2010) and the central nervous system (Lin et al., 2009).  Upregulated IGFBP2 
expression levels have been reported for various tumor tissues as well, and in many 
instances, these expression levels correlate with the grade of malignancy (Mishira et al., 1998; 
Pekonen et al., 1992; Fuller et al., 1999; Rickman et al., 2001; Sallinen et al., 2000).  Moreover, 
an inverse correlation between IGFBP2 and tumor suppressor genes, such as PTEN and 
p16/INK4, whose loss-of-function is frequently observed in malignant tumors, has also been 
reported (Perks et al., 2007; Moore et al., 2009).  Indeed, induction of PTEN downregulates 
IGFBP2 expression in glioblastoma and prostate cancer cells (Levitt et al., 2005; Mehrian-Shai 
et al., 2007).  On the other hand, the p53 tumor suppressor is suggested to be a transcription 
factor that stimulates IGFBP2 expression (Grimberg et al., 2006).  Hypoxia-induced 
expression of IGFBP2 mediated by hypoxia inducible factor 1ǂ (HIF1ǂ), has also been 
demonstrated (Feldser et al., 1999).  In sum, the expression of IGFBP2 can be significantly 
influenced by oncogenic genetic alteration and by a hypoxic tumor microenvironment, and 
many clinicopathological analyses strongly suggest that IGFBP2 participates in tumor 
progression. 
3.1.2 Expression of IGFBP2 in gliomas and its correlation with histological grade 
A consistent overexpression of IGFBP2 in glioblastoma was initially reported by Fuller et al. 
(1999) based on a gene expression profiling analysis.  This finding has since been confirmed 
by many researchers and it is now well established that IGFBP2 expression in gliomas 
increases with tumor grade (Sallinen et al., 2000; Rickman et al., 2001; Elminger et al., 2001; 
Fukushima & Kataoka, 2007).  Indeed, IGFBP2 is one of the most powerful discriminators to 
distinguish glioblastomas from low-grade gliomas in proteomic analyses (Jiang et al, 2006).  
Regarding a possible mechanism for IGFBP2 overexpression in glioblastoma, Mehrian-Shai 
et al. (2007) have identified IGFBP2 as the most significant molecular signature for loss of 
PTEN and activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.  Notably, 
glioblastoma is one of the cancers most commonly affected by PTEN abnormalities (Sulis & 
Parsons, 2003).  Enhanced activation of NF-κB signaling pathway in glioblastoma cells 
(Wang et al., 2004) may also be involved in the upregulation of IGFBP-2 transcription (Cazals 
et al., 1999). 
The prognostic impact of IGFBPs expression in patients with newly diagnosed glioblastoma 
was recently reported (Santosh et al., 2010), with protein expression of IGFBP2, IGFBP 3 and 
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IGFBP5 being significantly associated with shorter survival by univariate Cox regression 
analysis.  However, multivariate Cox proportional hazards model showed that only IGFBP3 
had independent prognostic impact.  Plasma levels of IGFBP2 can also predict clinical 
outcomes of patients with glioblastoma (Lin et al., 2009).  In that study, preoperative plasma 
IGFBP2 levels were significantly higher in high-grade glioma patients compared to low-
grade glioma patients, and are significantly correlated with recurrence and disease-free 
survival in glioblastoma patients. 
3.1.3 Expression of IGFBP2 in other brain tumors 
Analysis of tissue mRNA levels revealed that IGFBP2 expression is indicative of poor 
prognosis in patients with medulloblastoma (de Bont et al., 2008).   IGFBP2 is also expressed 
by meningiomas, and a high IGF-II/IGFBP2 mRNA ratio is a sign of biologically aggressive 
behavior in meningiomas (Nordqvist et al., 1997).  However, a subsequent study by the same 
group revealed that IGFBP6 mRNA is more informative than IGFBP2 for the evaluation of 
meningioma invasiveness (Nordqvist et al., 2002). 
3.2 Role of IGFBP2 in malignant progression of gliomas 
3.2.1 Role for IGFBP2 in glioma development 
As mentioned above, analyses of clinical samples revealed that IGFBP2 expression 
significantly correlates with disease progression of gliomas, suggesting a role for IGFBP2 in 
malignant progression.  Furthermore, a recent study using a glial-specific transgenic 
(RCAS/Ntv-a) mouse system indicated that IGFBP2 in combination with platelet-derived 
growth factor-ǃ (PDGFB) is also an oncogenic factor in glioma development (Dunlap et al., 
2007).  In this model, the expression of oncogenic IGFBP2 is negatively regulated by Ink4a-
Arf, and consequently, loss of Ink4a-Arf results in enhanced IGFBP2 expression (Moore et al., 
2009).  Indeed, the Ink4a-Arf locus is frequently deleted in human gliomas and IGFBP2 
expression is inversely correlated with p16INK4a status (Moore et al., 2009). 
Evidence regarding a role for IGFBP2 in glioma development also arose from a recent study 
of glioma stem cell (GSC) that was found to overexpress IGFBP2, which subsequently 
promoted GSC expansion and survival (Hsieh et al., 2010).  Notably Hedgehog-GLI1 
signaling regulates human glioma growth, GSC self-renewal, and tumorigenicity (Clement 
et al., 2007) and gene expression of IGFs and IGFBPs is upregulated by GLI transcription 
factors (Villani et al., 2010).  Therefore, an autocrine circuit of IGF/IGFBP2- or IGFBP2-
induced signaling may be established in GSCs via activation of Hedgehog-GLI1 signaling, 
which may contribute to the stemness of GSCs. 
3.2.2 Roles for IGFBP2 in malignant phenotypes of glioblastoma cells 
Glioblastoma is a devastating brain tumor with extremely poor prognosis (Clarke et al., 
2010). Significant invasiveness into surrounding brain parenchyma, increased mitotic 
activity, sustained angiogenesis and necrosis surrounded by palisaded atypical tumor cells 
are histological hallmarks of this untreatable tumor.  The major impediment to successful 
therapeutic intervention for glioblastomas is their diffuse invasive nature.  An in vitro study 
using a human glioblastoma cell line engineered to overexpress IGFBP2 revealed that 
IGFBP2 enhances glioblastoma cell invasiveness (Wang et al., 2003).  Similarly, a study using 
human glioblastoma cell lines in which IGFBP2 expression was knocked down by consistent 
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retroviral expression of IGFBP2 short hairpin RNA (shRNA) revealed that silencing of the 
IGFBP2 gene reduces in vitro invasiveness and in vivo aggressiveness of the cells (Fukushima 
et al., 2007).  Consistent with these studies, high levels of IGFBP2 expression were detected 
within the infiltrating tumor cells of human glioblastomas in vivo (de Groot et al., 2010).  
Therefore, IGFBP2 has a crucial role in glioblastoma invasion. 
IGFBP2 may also be implicated in glioblastoma angiogenesis.  In a cDNA-array analysis of 
53 patient biopsies, IGFBP2 was included in a prominent gene cluster that allowed 
discrimination between primary (de novo) and non-primary (secondary) glioblastomas 
(Godard et al., 2003).  This gene cluster is composed mostly of angiogenesis-related genes, 
including vascular endothelial growth factor (VEGF) and fms-related tyrosine kinase 1.  
Notably, in situ hybridization demonstrates coexpression of IGFBP2 and VEGF in 
pseudopalisading cells surrounding tumor necrosis, providing evidence for a possible 
involvement of IGFBP2 in angiogenesis (Godard et al., 2003).  It is reasonable to postulate 
that HIF1ǂ is responsible for the concomitant expression of VEGF and IGFBP2 (Carmeliet et 
al., 1998; Feldser et al., 1999).  In addition, an anti-apoptotic function of intracellular IGFBP2 
was recently reported in lung cancer cells (Migita et al., 2010), which may also have 
implications for the enhanced expression of IGFBP2 within glioblastoma cells around 
necrosis. 
Taken together, these results strongly indicate that IGFBP2 has significant roles in the 
development of the malignant phenotypes of glioblastoma. 
3.2.3 Potential mechanisms of IGFBP2 action in the invasive growth of glioblastoma 
cells 
Interaction of IGFBP2 with components of the pericellular matrices results in local 
sequestration of IGFs and then in an enhancement of cellular IGF-induced signaling (Schutt 
et al., 2004).  Experiments using a cultured neuroblastoma cell line showed that the heparin 
binding domain of IGFBP2 is required for IGFBP2 association to pericellular matrices and 
for IGFBP2 to promote invasive growth via efficient pericellular localization of IGF-1 (Russo 
et al., 2005). 
However, IGF-independent actions of IGFBP2 may be equally or more important in 
glioblastoma biology, as has been amply demonstrated by recent research.  Interaction of 
IGFBP2 RGD domain with integrin ǂ5 induces outside-in signaling and may be essential for 
IGFBP2-induced glioma cell mobility (Wang et al., 2006).  Moreover, intracellular 
localization of IGFBP2 has been shown in glioblastoma cells and other tumor cells such as 
lung carcinoma, which appears to influence the cellular gene expression signature 
(Fukushima & Kataoka, 2007; Migita et al., 2010).  Overexpression of IGFBP2 in the SNB19 
human glioblastoma cell line revealed that IGFBP2 enhances the invasiveness of these cells 
by up-regulating expression of invasion-associated gene products, such as extracellular 
matrix-degrading protease, MMP-2 (Wang et al., 2003).  We compared the expression 
profiles of two human glioblastoma cell lines, U251 and YKG-1, in the presence and absence 
of shRNA-induced silencing of IGFBP2 expression (Fukushima et al., 2007).  In both cell 
lines, expression levels of various genes were altered by IGFBP2 knockdown without 
apparent alteration of IGF signaling, suggesting that IGFBP2 influences transcriptional 
regulation of many genes in glioblastoma cells independent of IGF signaling.  Among the 
genes influenced by IGFBP2 silencing, the CD24 gene was identified as a candidate 
downstream target of IGFBP2-induced signaling, and subsequent analysis revealed that 
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CD24 is critically involved in the invasiveness of U251 and YKG-1 cells (Fukushima et al., 
2007).  CD24 is a heavily glycosylated, cell surface, glycosylphosphatidylinositol-anchored 
protein (Kristiansen et al., 2004).  While the precise mechanism by which CD24 induces 
cellular invasion is unclear, CD24 has been shown to recruit adhesion molecules to lipid 
rafts, thereby contributing to tumor cell migration, dissemination, and metastasis (Baumann 
et al., 2005; Runz et al., 2008).  Of interest is a recent observation that a splice variant of GLI1, 
truncated GLI1 (tGLI1), which is highly expressed in glioblastoma cells but not in normal 
cells, induces cellular migratory and invasive capabilities via upregulaton of CD24 in U87 
glioblastoma cells (Lo et al., 2009).  As mentioned above, Hedgehog-GLI1 signaling is 
involved in glioma cell growth, expansion of GSC and induction of IGFBP2 expression 
(Clement et al., 2007; Villani et al., 2010).  Therefore, Hedgehog-GLI1/IGFBP2/CD24 
signaling may play a pivotal role in the invasive growth of glioblastoma cells. 
The NF-κB pathway is another important candidate for the signaling involved in IGFBP2-
induced phenotypes.  In fact, NF-κB signaling is activated in glioblastomas and involved in 
invasion and angiogenesis of glioma cells (Wang et al., 2004; Li et al., 2007).  While NF-κB is 
suggested to regulate IGFBP2 gene expression in response to tissue injury (Cazals et al., 
1999), intracellular IGFBP2 itself is involved in the regulation of NF-κB signaling via binding 
to invasion inhibitory protein 45 (IIp45, also named migration and invasion inhibitor protein 
MIIP), which was identified by a yeast two-hybrid assay (Song et al., 2003).  The IIp45 gene is 
located on chromosome 1p36 (Song et al., 2003), a region that is frequently deleted in 
oligodendrogliomas and occasionally deleted in astrocytomas (Smith et al., 1999).  Decreased 
IIp45/MIIP levels were also observed in 15% of glioblastoma cases (Song et al., 2003).  
IIp45/MIIP binds to the RGD motif of IGFBP2 and inhibits the interaction between IGFBP2 
and integrin, which eventually may inhibit the expression of transcriptional NF-κB and its 
downstream genes involved in invasive glioma cell growth (Song et al., 2003).  It may be 
possible that upregulated NF-κB in the absence of IIp45/MIIP also stimulates IGFBP2 
transcription and eventually establishes an autocrine stimulation circuit for invasive growth.  
Moreover, recent studies have indicated that IIp45/MIIP also interacts with intracellular 
proteins, such as Cdc20 and histon deacetylase 6 (HDAC6), and inhibits glioma cell 
proliferation and migration (Ji et al., 2010; Wu et al., 2010).  Therefore, interaction between 
IIp45/MIIP and intracellular IGFBP2 may occur in glioblastoma cells, which may attenuate 
the function of IIp45/MIIP and thereby may enhance the cellular proliferation and 
migration. 
We summarize hypothetical functions of IGFBP2 in the invasive growth of glioblastoma 
cells in Figure 2. 
3.2.4 IGFBP2 as a therapeutic target for high-grade gliomas 
We have shown above that IGFBP2 can provide crucial signaling during glioma 
development and can exhibit malignant phenotypes of glioblastoma.  As such, IGFBP2 and 
its downstream targets may reasonably serve as novel therapeutic targets for glioblastoma.  
However, there have been limited attempts to target IGFBP2 for in vivo glioblastoma 
treatments.  Moore et al. (2009) examined the effect of antisense IGFBP2 in vivo using 
PDGFB-induced glioma in Ink4a-Arf-null mice, and found that the inhibition of IGFBP2 
expression confers a survival benefit.  Therefore, IGFBP2 is a potential therapeutic target for 
Ink4a-Arf-dleted gliomas, such as anaplastic oligodendroglioma and glioblastoma (Moore et 
al., 2009). 
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As a downstream molecule of IGFBP2 involved in invasiveness of glioblastoma cells, CD24 
may also serve as a molecular target for glioblastoma treatment.  Targeting CD24 by 
monoclonal antibodies, small interfering RNA or shRNA has been reported in xenograft 
models of human colorectal cancer, pancreatic cancer and ovarian cancer cell lines (Sagiv et 
al., 2008; Su et al., 2009).  In those studies, retardation of tumorigenicity and significant 
reduction of tumor growth were observed in vivo, indicating that CD24 is a promising 
therapeutic target for treatment of cancer.  As glioblastomas abundantly express CD24 as 
well as IGFBP2 (Fukushima et al., 2007), we suggest that targeting CD24 may be a potential 
therapeutic approach against glioblastoma. 
 
 
 
Fig. 2. Roles for IGFBP2 in the establishment of malignant phenotypes of glioblastoma cells.  
Both IGF-dependent and IGF–independent effects of IGFBP2 have been proposed.  Integrin-
mediated outside-in signaling and NF-κB signaling appear to be involved in the IGFBP2-
induced effects, which eventually result in enhanced expression of proinvasive molecules, 
such as CD24 and MMP-2.  While IIp45/MIIP may inhibit binding of IGFBP2 to integrin, it 
is possible to hypothesize that excess intracellular (intranuclear) IGFBP2 may suppress the 
inhibitory effects of IIp45/MIIP on Cdc20 and/or HDAC6-mediated cellular growth and 
migration.  The upregulated NF-κB signaling enhances the expression of IGFBP2. Hypoxic 
microenvironment, loss of PTEN function and Hedgehog-GLI1 signaling might also be 
involved in the enhanced IGFBP2 expression in glioblastoma cells.  Functions of intracellular 
and intranuclear IGFBP2 remain to be elucidated.  ECM, extracellular matrix. 
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IGFBP2 may also be an attractive marker to influence glioblastoma treatment strategy 
decisions.  Since high IGFBP2 levels serve as a marker for loss of PTEN function and 
PI3K/Akt activation, the clinical data linking IGFBP2 expression to poor prognosis may be 
due, at least in part, to the loss of PTEN function, which is well known to lead to aggressive 
behavior of gliomas (Levitt et al., 2005; Mehrian-Shai, 2007).  Therefore, measurements of 
IGFBP2 expression levels may be useful for estimating the functional PTEN status and 
PI3K/Akt activation levels in glioma, which in turn may be beneficial for organizing specific 
treatment strategies for each glioma case (Gonzalez & de Groot, 2008).  Moreover, recent 
study suggests that IGFBP2 expression level may be a marker for DNA hypermethylation 
profiles in gliomas (Zheng et al., 2011). 
4. Conclusion 
IGFBP2 is a pleiotropic protein that appears to be involved in many aspects of physiological 
and pathological processes and shows both positive and negative effects.  Even in cancers, 
opposite effects of IGFBP2 are observed.  For example, the growth of colorectal adenomas 
induced by chemical carcinogens in mice was inhibited upon crossing with IGFBP2 
transgenic mice (Diehl et al., 2008).  In contrast, IGFBP2 exerts oncogenic effects in brain-
specific transgenic mice (Dunlap et al., 2007; Moore et al., 2009).  Thus, IGFBP2 shows both 
negative and positive effects on tumor growth, and these differences are probably 
dependent on cell type and pericellular environment.  Despite the diverse effects of IGFBP2 
on the biological behaviors of cancers, it has been clearly demonstrated that IGFBP2 is 
overexpressed in a wide variety of human malignancies, and evidence is rapidly 
accumulating to indicate that IGFBP2 is significantly involved in the progression of glioma 
and confers malignant phenotypes of glioblastoma cells.  To clarify the molecular 
mechanisms underlying the effects of IGFBP2 on gliomas, not only the pericellular IGF-
dependent and IGF-independent functions but also the functions of intracellular IGFBP2 
should be defined (Figure 2).  Additional information concerning the factors that directly 
regulate IGFBP2 overexpression in gliomas and those that are critically involved in the 
IGFBP2-mediated malignant features of glioblastoma cells is required and may lead to new 
therapeutic avenues for one of the most treatment-resistant human tumors. 
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